CNS Pharmaceuticals, Inc.
2100 West Loop South, Suite 900
Houston, TX 77027
December 14, 2023
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
| Re: | CNS Pharmaceuticals, Inc. | |
| Registration Statement on Form S-1 (the “Registration Statement”) | ||
| File No. 333-275973 |
Ladies and Gentlemen:
Pursuant to Rule 461 of the Securities Act of 1933, as amended, CNS Pharmaceuticals, Inc., a Nevada corporation (the “Company”), hereby respectfully requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 5:00 P.M. (Eastern Time) on December 18, 2023, or as soon thereafter as possible on such date.
We request that we be notified of such effectiveness by a telephone call to Cavas Pavri at (202) 724-6847 of ArentFox Schiff LLP, and we request that such effectiveness also be confirmed in writing.
| Very truly yours, | |
|
CNS Pharmaceuticals, Inc. | |
| By: /s/ Christopher Downs | |
| Name: Christopher Downs | |
| Title: Chief Financial Officer |
cc: Cavas Pavri, ArentFox Schiff LLP